Cetuximab and FOLFOX6 for Advanced Gastric Cancer
Author Information
Author(s): Han S-W, Oh D-Y, Im S-A, Park S R, Lee K-W, Song H S, Lee N-S, Lee K H, Choi I S, Lee M H, Kim M A, Kim W H, Bang Y-J, Kim T-Y
Primary Institution: Seoul National University Hospital
Hypothesis
EGFR and its ligands predict cetuximab efficacy in AGC.
Conclusion
Cetuximab combined with modified FOLFOX6 showed promising results in patients with EGFR expression and low serum ligand levels.
Supporting Evidence
- Among 38 evaluable patients, confirmed response rate was 50.0%.
- Median time-to-progression was 5.5 months.
- Overall survival was 9.9 months.
- Patients with EGFR expression and low ligand levels had a 100% response rate.
Takeaway
This study looked at a medicine called cetuximab combined with chemotherapy to help people with stomach cancer. It found that some patients did really well if they had certain markers in their body.
Methodology
This was a prospective multicentre phase II study where patients received cetuximab and modified FOLFOX6, and biomarkers were analyzed.
Limitations
The sample size was not large enough to test the differences between the statuses of various biomarkers.
Participant Demographics
{"total_patients":40,"male":30,"female":10,"median_age":55,"age_range":"33-74"}
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 34.1–65.9
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website